New Apabetalone Fabry Disease Publication
posted on
Apr 26, 2022 07:27AM
Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy
https://pubmed.ncbi.nlm.nih.gov/35417091/
Pharmacol Res Perspect. 2022 Jun;10(3):e00949.
PMID: 35417091 PMCID: PMC9007222 DOI: 10.1002/prp2.949